In an interview with the Johns Hopkins Malaria Minute, Dr. William Moss, IVAC's Executive Director and Deputy Director at the Johns Hopkins Malaria Research Institute, discusses the significance of newly developed malaria vaccines. Dr. Moss explained, "This is a very exciting time for malaria vaccines as we now have two vaccines that have been recommended by the World Health Organization."
This month, IVAC faculty presented findings from their research on leveraging social media influencers to combat vaccine disinformation at the 2024 Knight Media Forum, a leading conference for media and journalism. Dr. Rupali Limaye received a grant from the Knight Foundation as part of a call for projects combating the impacts of disinformation on communities of color in the United States. The team designed and tested an educational training resource with Latinx social media users and community leaders to provide evidence-based strategies to combat disinformation in Spanish-speaking communities. The resource can be accessed in English or Spanish here.
This playbook from the Johns Hopkins Center for Health Security is designed to help public health and medical professionals and other health communicators understand when to step in and what actions to take to address rumors and misinformation related to public health issues.
User Survey: Feedback Requested Help us improve our newsletter! Please complete a 5-minute, anonymous survey to give us a better idea of the type of news and resources you find most useful.
In the midst of a global cholera vaccine shortage and mounting cholera cases, a new study led by researchers at Johns Hopkins Bloomberg School of Public Health finds that a single dose of the vaccine provides significant protection against cholera for at least three years. This evidence is especially encouraging for expanding coverage among at-risk populations. “In cholera endemic areas, use of a one dose oral cholera vaccine regimen, rather than the standard two doses may allow us to greatly improve the population-level benefits of the vaccine with little to no reduction in protection to the individual, at least over the first few years,” explained Dr. Andrew Azman, Associate Scientist in the Bloomberg School's Department of Epidemiology and a senior author of the paper.
Subscribe to IVAC Channel on YouTube IVAC's YouTube channel has over 100 videos including short documentaries, recorded webinars, and tutorials for vaccine-related resources. Catch up on published videos and subscribe today to get notified when new videos are available.
During the COVID-19 pandemic, the COVID-19 Scenario Modeling Hubgenerated projections of disease burden in the United States to help with pandemic planning and decision-making. This publication describes the history of this massive collective research effort, the process of convening and maintaining an open modeling hub active over multiple years, and the expansion of the hub to generate influenza projections.
This qualitative study interviewed 13 global stakeholders to understand factors affecting the introduction and scale-up of HPV vaccination programs in LMICs. The results of this investigation identified upstream and downstream determinants that impact program introduction and scale-up and confirmed that strong political commitment and governance are needed to garner support for HPV vaccines.
To understand the relationship between integrated vaccine delivery and vaccination equity in LMICs, the authors analyzed longitudinal data relating to routine immunization coverage and vaccination equity in 78 LMICs that have received support from Gavi, the Vaccine Alliance. They concluded that integrated vaccine delivery is most strongly associated with improvements in vaccination equity in settings with high baseline levels of inequity.
In an interview with the 
